Physicians' Academy for Cardiovascular Education

ACS

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD

Neutral outcomes for early intervention strategy compared to standard strategy in NSTEMI patients

3' education - Aug. 28, 2018 - Prof. Thomas Engstrom, Copenhagen, Denmark

P2Y12 inhibitor monotherapy for 23 months after 1 month of DAPT, compared to traditional 12-month DAPT

3' education - Aug. 27, 2018 - Prof. Patrick Serruys, Rotterdam, The Netherlands

Treatment with statin before PCI intervention reduces MACE in patients with ACS

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, VS - Otavio Berwanger - São Paulo, Brasil

Results ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Treatment of patients on oral anticoagulation who present with ACS

10' education - Sep. 15, 2017 - Dr. Jur ten Berg - Cardiologist, Nieuwegein, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Customising therapy approach in ACS based on underlying pathology seems promising

3' education - Oct. 21, 2016 - ESC - 2016 Rome - Ik-Kyung Jang, MD - Massachusetts General Hospital, Boston, MA, USA

No added value of monitoring platelet function after ACS

3' education - Oct. 6, 2016 - ESC - 2016 Rome - Stefan Gielen, MD - University of Leipzig, Germany
##SCROLLER_ITEMS_FULL_TITLE##

No indication for difference in efficacy between potent platelet inhibitors after PCI

3' education - Aug. 30, 2016 - ESC - 2016 Rome - Steen Dalby Kristensen, MD - Aarhus University, Denmark

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

10' education - Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

Evolving hypotheses on the mechanisms underlying ACS

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter Libby, MD - Boston, MA, USA

Changing views on mechanisms of atherosclerosis

10' education - Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)

C-Reactive Protein, Inflammation and Atherosclerosis

Jan. 24, 2016
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation as target for therapy in atherothrombosis

10' education - Aug. 31, 2015 - ESC London - Prof Paul M Ridker
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation and Thrombosis

10' education - Sep. 29, 2015
##SCROLLER_ITEMS_FULL_TITLE##

The changing character of atherosclerotic disease

3' education - May 24, 2015 - ISA2015, Amsterdam - Prof. Peter Libby

Cardiovascular Inflammation and Immunity in Atherosclerosis:

10' education - June 7, 2015 - Amsterdam
##SCROLLER_ITEMS_FULL_TITLE##

HDL mimetics: New promise in ACS?

3' education - Sep. 15, 2014 - Barcelona 2014 - Prof Kausik Ray MD
##SCROLLER_ITEMS_FULL_TITLE##

New registries on ACS/PCI: how does the real world look like

10' education - Sep. 2, 2014 - Barcelona, ESC - Peter Sinnaeve, MD UZ Leuven
##SCROLLER_ITEMS_FULL_TITLE##

Latest guidelines on ACS/PCI: what are the key changes?

10' education - Sep. 2, 2014 - Barcelona, ESC - Prof. Petr Widimsky, Prague, Czech Republic
##SCROLLER_ITEMS_FULL_TITLE##

ACS/PCI :Patient cases based on real world data

10' education - Sep. 2, 2014 - Barcelona, ESC - Peter Sinnaeve, MD UZ Leuven
##SCROLLER_ITEMS_FULL_TITLE##

ACS/PCI: Patient cases based on latest guidelines

10' education - Sep. 1, 2014 - Barcelona, ESC - Professor Petr Widimský

Statin-loaded HDL nanoparticles

10' education - Jan. 23, 2014 - Raphaël Duivenvoorden - Raphaël Duivenvoorden

Benefits of dual COMPASS regimen also seen in patients with moderate renal dysfunction

Literature - May 21, 2019 - Fox KAA et al., - J Am Coll Cardiol. 2019

An analysis of the COMPASS trial in patients with GFR ≥60 or <60 mL/min showed consistent treatment benefit of the combination of rivaroxaban 2.5 mg bd plus aspirin, vs aspirin alone.

FDA expands indication for PCSK9 inhibitor to prevent major CV events in adults with CVD

News - May 6, 2019

The FDA has approved alirocumab to reduce the risk of MI, stroke, and unstable angina requiring hospitalization in adults with established CVD, based on ODYSSEY OUTCOMES data.

Guided DAPT de-escalation therapy in PCI-treated ACS patients with diabetes vs. non-diabetes

Literature - May 1, 2019 - Hein R, et al. - EuroIntervention 2019

No interaction was observed between diabetes status, guided DAPT de-escalation therapy vs. control therapy and outcomes in ACS patients after PCI.

Challenges for screening and treatment of FH patients in clinical cardiology

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh
Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.

Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.

Large absolute benefit with PCSK9 inhibitor in ACS patients with polyvascular disease

Literature - Mar. 27, 2019 - Jukema JW, et al. - JACC 2019

A prespecified analysis of the ODYSSEY OUTCOMES trial showed a higher incidence of MACE and death in ACS patients with polyvascular disease and alirocumab treatment resulted in a large absolute benefit in these patients.

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD
Dr. John Alexander summarizes the main findings of the AUGUSTUS trial, in which apixaban yielded better results than warfarin, and those not on aspirin did better than those taking aspirin, in patients with AF and a recent ACS/PCI.

ACC 2019 Dr. John Alexander summarizes the main findings of the AUGUSTUS trial, in which apixaban yielded better results than warfarin, and those not on aspirin did better than those taking aspirin, in patients with AF and a recent ACS/PCI.

Antithrombotic regime with NOAC but no aspirin most favorable for patients with AF and ACS/PCI

News - Mar. 17, 2019

ACC 2019 The AUGUSTUS trial showed less bleeding and fewer hospitalizations without differences in ischemic events with apixaban and no aspirin, as compared with regimens with VKA, aspirin or both.

hsCRP levels at and after ACS associated with risk of recurrent MACE and death

Literature - Mar. 12, 2019 - Mani P et al., - JAMA Cardiol. 2019

In a secondary analysis of the VISTA-16 trial, hsCRP levels measured at the time of ACS and increases of hsCRP in the 16 weeks after, were correlated with MACE, all-cause and CV death.

Retraction of meta-analysis on statin loading pre-PCI for ACS

News - Mar. 1, 2019

RETRACTION 7 Out of 13 studies included in a meta-analysis of RCTs on atorvastatin loading prior to PCI for ACS should have been excluded based on the study’s selection criteria. A corrected analysis substantively alters the results.

Evaluation of DAPT duration in post-PCI patients stratified for bleeding score and ischemic risk

Literature - Feb. 28, 2019 - Costa F et al. - JACC 2019
A retrospective analysis of RCTs suggests that when ischemic and bleeding risks are concordant, bleeding risk should inform decision-making on DAPT duration more so than ischemic risk.

A retrospective analysis of RCTs suggests that when ischemic and bleeding risks are concordant, bleeding risk should inform decision-making on DAPT duration more so than ischemic risk.

Transportation noise linked to MI mortality in adults, independently of air pollution

Literature - Feb. 26, 2019 - Héritier H et al. - Eur Heart J 2018

Noise from road traffic, railway and aircraft were associated with MI mortality in a cohort of adults, independently of air pollution, in a model that assessed individual exposure at the address and floor level.

Diet drinks associated with increased risk of CV outcomes and all-cause mortality in postmenopausal women

Literature - Feb. 25, 2019 - Mossavar-Rahmani Y et al. - Stroke 2019

Self-reported consumption of ≥2 artificially sweetened beverages per day was associated with higher risk of CV events, and all-cause mortality in postmenopausal women, as shown in an observational study.